Breaking News
Sort by:
Top Post
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBITM (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Eisai and Biogen announced today that the US Food and Drug Administration (FDA) has accepted […]
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, […]
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050, a Novel Individualized Neoantigen Cancer Vaccine
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment […]
- Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa Read more
- Celyad Oncology Appoints Georges Rawadi as Its New CEO Read more
- Companion Spine Closes $60.1 Million Series A Funding Round Read more
- EVERSANA® Announces Partnership with ChemoMouthpiece, LLC to Support U.S. Launch & Commercialization of Medical Device to Help Cancer Patients Manage and Treat Oral Mucositis Read more
- Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer Read more